Yifan Lian
Overview
Explore the profile of Yifan Lian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei H, Luo S, Bi Y, Liao C, Lian Y, Zhang J, et al.
Liver Res
. 2025 Feb;
8(2):105-117.
PMID: 39959877
Background And Aims: Hepatocellular carcinoma (HCC), which is prevalent worldwide and has a high mortality rate, needs to be effectively diagnosed. We aimed to evaluate the significance of plasma microRNA-15a/16-1...
2.
Lin H, Ma Z, Li J, Zhu H, Huang X, Chen H, et al.
Front Immunol
. 2025 Jan;
15:1500863.
PMID: 39867901
Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate...
3.
Zhang D, Zhang E, Cai Y, Sun Y, Zeng P, Jiang X, et al.
Hereditas
. 2025 Jan;
162(1):6.
PMID: 39844327
Background: Pancreatic cancer is one of the most malignant abdominal tumors. DDX60 has been shown to be associated with a variety of tumor biological processes. However, DDX60 in pancreatic cancer...
4.
Zhang D, Cai Y, Sun Y, Zeng P, Wang W, Wang W, et al.
Drug Dev Res
. 2025 Jan;
86(1):e70045.
PMID: 39821365
Famotidine is an H2 receptor antagonist and is currently used on a large scale in gastroenterology. However, Famotidine may also cause severe toxicity to organ systems, including the blood system,...
5.
Zhang D, Cai Y, Sun Y, Zeng P, Wang W, Wang W, et al.
Front Pharmacol
. 2025 Jan;
15:1442765.
PMID: 39741633
Aims: The primary objective of this study was to closely monitor and identify adverse events (AEs) associated with Sorafenib, a pharmacological therapeutic agent used to treat hepatocellular carcinoma, renal cell...
6.
Wei H, Bi Y, Liao C, Huang Y, Lian Y
Noncoding RNA Res
. 2024 Sep;
9(4):1342-1350.
PMID: 39247146
Background: The lack of effective non-invasive diagnostic methods for liver fibrosis hinders timely treatment for chronic hepatitis B (CHB) patients, leading to the progression of advanced liver disease. Circulating microRNAs...
7.
Li X, Gu Y, Liao C, Ma X, Bi Y, Lian Y, et al.
Int Immunopharmacol
. 2024 Aug;
140:112848.
PMID: 39096876
Background: Chronic hepatitis B virus (HBV) infection is a serious human health threat given its high morbidity and mortality. Timely and effective antiviral treatment can postpone liver disease progression and...
8.
Cai Y, Chen Z, Chen E, Zhang D, Wei T, Sun M, et al.
Inflammation
. 2024 Apr;
47(6):2000-2012.
PMID: 38613638
Autoimmune hepatitis (AIH) is a severe immune-mediated inflammatory liver disease that currently lacks feasible drug treatment methods. Our study aimed to evaluate the protective effect of succinic acid against AIH...
9.
Yang J, Lian Y, Yang R, Lian Y, Wu J, Liu J, et al.
Mol Ther Nucleic Acids
. 2024 Jan;
35(1):102108.
PMID: 38204915
[This retracts the article DOI: 10.1016/j.omtn.2019.12.041.].
10.
Wang J, Zhang X, Ma X, Chen D, Cai M, Xiao L, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):303.
PMID: 37968706
Background: Despite remarkable advancements in cancer immunotherapy, the overall response rate to anti-programmed cell death-1 (anti-PD-1) therapy in hepatocellular carcinoma (HCC) patients remains low. Our previous study has demonstrated the...